Evidence map›Paper›PMID 27889643›Full record

ArticleNeoplasia (New York, N.Y.)2016

Multimodality Imaging Identifies Distinct Metabolic Profiles In Vitro and In Vivo.

Marie-Aline Neveu, Géraldine De Preter, Valérie Marchand, Anne Bol, Jeffery R Brender, Keita Saito, Shun Kishimoto, Paolo E Porporato, Pierre Sonveaux, Vincent Grégoire and 4 more

Abstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Multimodal Imaging of Hypoxia, Metabolism and pH in Feline Sarcoma Using HyperpolarizedAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marie-Aline NeveuBiomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium.
Géraldine De PreterBiomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium.
Valérie MarchandBiomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium.
Anne BolRadiation Oncology Department & Center for Molecular Imaging, Radiotherapy & Oncology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain, Brussels, Belgium.
Jeffery R BrenderRadiation Biology Branch, National Cancer Institute, NIH, Bethesda, USA.
Keita SaitoRadiation Biology Branch, National Cancer Institute, NIH, Bethesda, USA.
Shun KishimotoRadiation Biology Branch, National Cancer Institute, NIH, Bethesda, USA.
Paolo E PorporatoPole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain, Brussels, Belgium.
Pierre SonveauxPole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain, Brussels, Belgium.
Vincent GrégoireRadiation Oncology Department & Center for Molecular Imaging, Radiotherapy & Oncology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain, Brussels, Belgium.
Olivier FeronPole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain, Brussels, Belgium.
Bénédicte F JordanBiomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium.
Murali C KrishnaRadiation Biology Branch, National Cancer Institute, NIH, Bethesda, USA.
Bernard GallezBiomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels, Belgium. Electronic address: bernard.gallez@uclouvain.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study of alterations of tumor metabolism should allow the identification of new targets for innovative anticancer strategies. Metabolic alterations are generally established in vitro, and conclusions are often extrapolated to the in vivo situation without further tumor metabolic phenotyping. To highlight the key role of microenvironment on tumor metabolism, we studied the response of glycolytic and oxidative tumor models to metabolic modulations in vitro and in vivo. MDA-MB-231 and SiHa tumor models, characterized in vitro as glycolytic and oxidative, respectively, were studied. Theoretically, when passing from a hypoxic state to an oxygenated state, a Warburg phenotype should conserve a glycolytic metabolism, whereas an oxidative phenotype should switch from glycolytic to oxidative metabolism (Pasteur effect). This challenge was applied in vitro and in vivo to evaluate the impact of different oxic conditions on glucose metabolism.

Indexed as

MetabolomeMultimodal ImagingAnimalsCell Line, TumorDisease Models, AnimalElectron Spin Resonance SpectroscopyGlucoseGlycolysisHeterograftsHumansMagnetic Resonance SpectroscopyNeoplasmsOxidation-ReductionOxygenPhenotypePositron Emission Tomography Computed TomographyGlucoseOxygen

Identifiers

PMID27889643
PMCPMC5126136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.